To Assess Analgesia Provided by Continuous Sciatic Nerve Block in Patients With Hypertensive Leg Ulcer (ANGIOCATH)
Hypertensive leg ulcer, also called Martorell ulcer, represents 1 to 15% of leg ulcers in hospital. These ulcers are painful, long to heal, and hospitalization is sometimes necessary for analgesia and debridement of necrotic tissue. Strong opioids are often required, and are responsible of many side effects. Martorell ulcer arises predominantly in women over 60 years of age, with history of vascular disease, and therefore with a higher risk of adverse event. Pain is also part of the physiopathology, inducing a vasospasm which increases ulcer extension and ischemia.
This is why pain management is one of the main challenge in treatments of these ulcers.
Continuous nerve block of lower limbs are often used during per and postoperative orthopaedic surgery. Few adverse events and rare serious adverse events related to local anesthesic are reported (respectively <1% and <1/1000), and few adverse events related to catheter are reported (<1%). Its benefits have been proved on post-operative pain management and reeducation.
The aim of this study is to assess analgesia provided by continuous sciatic nerve block, in patients with hypertensive leg ulcer, during hospitalization.
Thirty patients will be enrolled on a 3-years period. They will receive a continuous sciatic nerve block with ropivacaïne 0,2%, during 7 days.
Pain intensity will be assessed by 4 datas : numerating rating scale (NRS) at rest, during wound care, maximal and mean. These datas will be collected over two 3-days period : the first 3 days of hospitalization, in which pain treatment will be prescribed depending on pain intensity of the patient ; and the first 3 days of ropivacaïne treatment.
The main evaluation criteria will be at least a 50% decrease of one of the pain NRS when receiving ropivacaïne.
Time to healing, microcirculation evolution measured by Transcutaneous Oxygen Pressure (TcPO2), and quality of life of patients will be collected over a 6 months follow-up.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Monocentric Prospective Study, in Order to Assess Analgesia Provided by Continuous Sciatic Nerve Block, in Patients With Hypertensive Leg Ulcer.|
- number of patient with a 50% decrease of one of the pain NRS [ Time Frame: 3 days ] [ Designated as safety issue: No ]The main evaluation criteria will be at least a 50% decrease of one of the pain NRS (at rest, during wound care, maximal or mean) with 3 days of ropivacaïne treatment, compared to 3 days of usual analgesic treatment.
- Evolution of NRS [ Time Frame: 6 month ]NRS during the 7 days of ropivacaïne, and during the 6 months follow up
- To assess patients's satisfaction with Patient Global Impression of Change [ Time Frame: 6 month ]
- To assess quality of life using Short Form 36 (SF36) [ Time Frame: 6 month ]Quality of life using a standardized questionnaire : SF36
- To assess pain consequences using Hospital Anxiety and Depression Scale (HAD) and Brief Pain Inventory questionnaire(BPI) [ Time Frame: 6 month ]Pain consequences using standardized questionnaire : HAD, BPI
- To assess microcirculatory evolution with a TCPO2 measure [ Time Frame: 6 month ]Microcirculatory evolution with a TCPO2 measure before and after ropivacaïne treatment
|Study Start Date:||February 2014|
|Estimated Study Completion Date:||May 2017|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN <3/10 : non opioids, EN 3-5/10 : weak opioids, EN>5/10 : strong opioids).
If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.
In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01964911
|Contact: Cécile DURANT, Dr||02 40 08 78 55|
|Nantes University Hospital||Recruiting|
|Nantes, France, 44093|
|Contact: Cécile DURANT, Dr 02 40 08 78 55|
|Contact: Joséphine THOMAZEAU, Ms.|
|Principal Investigator: Cécile DURANT, Dr|
|Principal Investigator:||Cécile DURANT, Dr||Nantes University Hospital|